Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Altimmune, Inc.

ALT · Nasdaq · CIK 0001326190 · Healthcare · Biotechnology

INSIDER SIGNAL

38.1 / 100

1 buyers · 1 purchase transaction lines · $44.2K gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeLow
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35
Purchase size+4.8 / 25
Role+13.0 / 20
Recency+3.3 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Role scores low · most senior buyer: President and CEO (CEO, chair and 10% owners score lowest)
  • ⚠ Purchase activity is becoming less recent

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
WEAVER GREGORY LChief Financial Officer
○○○
Richardson Linda MChief Commercial Officer
○○
Arbet-Engels ChristopheChief Medical Officer
○○
Durso Jerome BenedictPresident and CEO
●
Roberts M ScotChief Scientific Officer
○
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: Durso Jerome Benedict · $44.2K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-08-13–2026-08-13

Roles in the peak window: President and CEO. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

38.1 / 100

Latest recorded score

↓ -0.1 ptsversus the previous recorded snapshot
  1. 38.5
  2. 38.5
  3. 38.4
  4. 38.2
  5. 38.1

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

11Purchases
0Sales
33Other Form 4 lines
27SEC filings · 365 days
BUYING1 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER8 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot detected in parsed evidence

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-20.7%
3M
-12.7%
6M
-19.4%
12M
-33.6%

Volatility & liquidity

Volatility
82.0%
Beta
—
Avg daily value
USD 11.1M

Valuation

Market cap
USD 507.7M
P/E
—

Fundamentals

Profit margin
—
ROE
-39.2%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-07 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
46,079,911
Previous report
51,749,756
Avg daily volume
4,373,581
Days to cover
10.5

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-13Durso Jerome BenedictPurchase (P)Common Stock, par value $0.000115,000USD 2.95USD 44,250SEC filing ↗
2026-04-06GILL JOHNPurchase (P)Common Stock, par value $0.00019,200USD 3.41USD 31,372SEC filing ↗
2026-04-01WEAVER GREGORY LPurchase (P)Common Stock, par value $0.000110,000USD 3.15USD 31,500SEC filing ↗
2026-04-01Durso Jerome BenedictPurchase (P)Common Stock, par value $0.000115,000USD 3.14USD 47,100SEC filing ↗
2026-03-06WEAVER GREGORY LPurchase (P)Common Stock, par value $0.00015,000USD 3.54USD 17,700SEC filing ↗
2026-03-06Durso Jerome BenedictPurchase (P)Common Stock, par value $0.000120,000USD 3.54USD 70,800SEC filing ↗
2026-01-08Pisano WaynePurchase (P)Common Stock, par value $0.00015,000USD 4.08USD 20,400SEC filing ↗
2026-01-05Sohn Catherine A.Purchase (P)Common Stock, par value $0.0001500USD 4.24USD 2,120SEC filing ↗
2025-12-29Jorkasky DianePurchase (P)Common Stock, par value $0.0001527USD 3.80USD 2,003SEC filing ↗
2025-12-23GILL JOHNPurchase (P)Common Stock, par value $0.000112,500USD 4.10USD 51,250SEC filing ↗
2025-12-22Durso Jerome BenedictPurchase (P)Common Stock, par value $0.000112,500USD 4.13USD 51,625SEC filing ↗
2025-03-17Sohn Catherine A.Purchase (P)Common Stock, par value $0.00011,000USD 5.78USD 5,780SEC filing ↗
2025-03-13WEAVER GREGORY LPurchase (P)Common Stock, par value $0.000110,000USD 5.20USD 52,000SEC filing ↗
2023-08-15Drutz DavidPurchase (P)Common Stock, par value $0.0001300USD 2.88USD 864SEC filing ↗
2023-03-24Eisenstadt Richard IPurchase (P)Common Stock, par value $0.000110,000USD 4.31USD 43,100SEC filing ↗

Form 4 evidence

44 transaction lines in the latest 365-day window; 262 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-01WEAVER GREGORY LOption exercise / conversion (M)Common Stock, par value $0.000114,475USD 0.00USD 0SEC filing ↗
2026-10-01WEAVER GREGORY LTax withholding (F)Common Stock, par value $0.00014,379USD 2.76USD 12,086SEC filing ↗
2026-10-01Arbet-Engels ChristopheOption exercise / conversion (M)Common Stock, par value $0.000137,500USD 0.00USD 0SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-01WEAVER GREGORY LOption exercise / conversion (M)Common Stock, par value $0.000114,475USD 0.00USD 0SEC filing ↗
2026-10-01WEAVER GREGORY LTax withholding (F)Common Stock, par value $0.00014,379USD 2.76USD 12,086SEC filing ↗
2026-10-01Arbet-Engels ChristopheOption exercise / conversion (M)Common Stock, par value $0.000137,500USD 0.00USD 0SEC filing ↗
2026-10-01Arbet-Engels ChristopheTax withholding (F)Common Stock, par value $0.000112,679USD 2.76USD 34,994SEC filing ↗
2026-09-16Richardson Linda MOption exercise / conversion (M)Common Stock, par value $0.000124,000USD 0.00USD 0SEC filing ↗
2026-09-16Richardson Linda MTax withholding (F)Common Stock, par value $0.00016,826USD 3.24USD 22,116SEC filing ↗
2026-08-13Durso Jerome BenedictPurchase (P)Common Stock, par value $0.000115,000USD 2.95USD 44,250SEC filing ↗
2026-07-31WEAVER GREGORY LAward / grant (A)Common Stock, par value $0.00011,753USD 2.41USD 4,225SEC filing ↗
2026-07-31Roberts M ScotAward / grant (A)Common Stock, par value $0.0001875USD 2.41USD 2,109SEC filing ↗
2026-04-06GILL JOHNPurchase (P)Common Stock, par value $0.00019,200USD 3.41USD 31,372SEC filing ↗
2026-04-01WEAVER GREGORY LPurchase (P)Common Stock, par value $0.000110,000USD 3.15USD 31,500SEC filing ↗
2026-04-01Durso Jerome BenedictPurchase (P)Common Stock, par value $0.000115,000USD 3.14USD 47,100SEC filing ↗
2026-03-06WEAVER GREGORY LPurchase (P)Common Stock, par value $0.00015,000USD 3.54USD 17,700SEC filing ↗
2026-03-06Durso Jerome BenedictPurchase (P)Common Stock, par value $0.000120,000USD 3.54USD 70,800SEC filing ↗
2026-02-02Roberts M ScotOption exercise / conversion (M)Common Stock, par value $0.00017,775USD 0.00USD 0SEC filing ↗
2026-02-02Roberts M ScotTax withholding (F)Common Stock, par value $0.00012,329USD 5.55USD 12,926SEC filing ↗
2026-01-31Roberts M ScotAward / grant (A)Common Stock, par value $0.00015,567USD 3.07USD 17,091SEC filing ↗
2026-01-31Jordt Raymond MAward / grant (A)Common Stock, par value $0.00014,571USD 3.07USD 14,033SEC filing ↗
2026-01-31Garg Vipin KAward / grant (A)Common Stock, par value $0.00016,926USD 3.07USD 21,263SEC filing ↗
2026-01-30Roberts M ScotOption exercise / conversion (M)Common Stock, par value $0.00019,275USD 0.00USD 0SEC filing ↗
2026-01-30Roberts M ScotTax withholding (F)Common Stock, par value $0.00012,859USD 5.60USD 16,010SEC filing ↗
2026-01-30Garg Vipin KOption exercise / conversion (M)Common Stock, par value $0.000126,775USD 0.00USD 0SEC filing ↗
2026-01-30Garg Vipin KTax withholding (F)Common Stock, par value $0.000111,632USD 5.60USD 65,139SEC filing ↗
2026-01-27Roberts M ScotOption exercise / conversion (M)Common Stock, par value $0.000115,850USD 0.00USD 0SEC filing ↗
2026-01-27Roberts M ScotTax withholding (F)Common Stock, par value $0.00014,748USD 6.18USD 29,343SEC filing ↗
2026-01-27Jordt Raymond MOption exercise / conversion (M)Common Stock, par value $0.000115,850USD 0.00USD 0SEC filing ↗
2026-01-27Jordt Raymond MTax withholding (F)Common Stock, par value $0.00014,229USD 6.18USD 26,135SEC filing ↗
2026-01-27Garg Vipin KOption exercise / conversion (M)Common Stock, par value $0.000141,200USD 0.00USD 0SEC filing ↗
2026-01-27Garg Vipin KTax withholding (F)Common Stock, par value $0.000117,898USD 6.18USD 110,610SEC filing ↗
2026-01-25Roberts M ScotOption exercise / conversion (M)Common Stock, par value $0.000114,600USD 0.00USD 0SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerALT
CIK0001326190
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history262 transaction lines from 2020-01-30 to 2026-10-01
27 P purchase lines · 21 S sale lines · 214 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.